Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma

被引：0
|
作者：
Yarchoan, Mark
Gane, Edward J.
Marron, Thomas U.
Perales-Linares, Renzo
Yan, Jian
Cooch, Neil
Shu, Daniel
Fertig, Elana J.
Kagohara, Luciane T.
Bartha, Gabor
Northcott, Josette
Lyle, John
Rochestie, Sarah
Peters, Joann
Connor, Jason
Jaffee, Elizabeth
Perales-Puchalt, Alfredo
Weiner, David B.
Csiki, Ildiko
Sardesai, Niranjan Y.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1191
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?
    Ladekarl, Morten
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (02)
  • [22] Second-line treatment of advanced neuroendocrine carcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (04): : 304 - 304
  • [23] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [24] Regorafenib promising second-line treatment in hepatocellular carcinoma
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (08) : 446 - 446
  • [25] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [26] Advancements in second-line treatment research for hepatocellular carcinoma
    Sun, Ruirui
    Wu, Chenrui
    Gou, Yang
    Zhao, Yaowu
    Huang, Ping
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03): : 837 - 857
  • [27] Preserving the Liver for Second-Line Treatment of Hepatocellular Carcinoma
    Lencioni, Riccardo
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 6 - 8
  • [28] How to Choose Second-Line Treatment for Hepatocellular Carcinoma
    Frenette, Catherine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 726 - 729
  • [29] Pembrolizumab: A reliable second-line treatment option for advanced esophageal cancer
    Zheng, Li
    Zhu, Yabi
    Liu, Yangyang
    Ma, Xu
    Xu, Fang
    THORACIC CANCER, 2022, 13 (08) : 1233 - 1233
  • [30] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
    Shao, Y. -Y.
    Chen, B. -B.
    Ou, D. -L.
    Lin, Z. -Z.
    Hsu, C. -H.
    Wang, M. -J.
    Cheng, A. -L.
    Hsu, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (08) : 722 - 730
12345